• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Business News Diaspora

Remdesivir has received FDA’s emergency approval to treat COVID-19, according to Trump

Emmanuel Abara Benson by Emmanuel Abara Benson
May 2, 2020
in Diaspora, Socio Economic
Remdesivir, new covid-19 strain
Share on FacebookShare on TwitterShare on Linkedin

President Donald Trump said the remdesivir drug has been given emergency use authorisation by the FDA to treat Coronavirus patients in the United States of America. Trump made the announcement yesterday during a televised address that was covered by CNBC. 

What we know: The remdesivir drug is manufactured by American pharmaceutical company, Gilead Sciences. Data from the Coronavirus trial testing of the drug showed that patients who took it recovered within eleven days. This indicates a shortened recovery period, compared to other drugs that have been used to treat the virus. 

More on the drug: Gilead Sciences’ Chief Executive Officer, Daniel O’Day, who was present during Trump’s live announcement, used the occasion “to thank the collaborators that brought remdesivir to this point and many of our people that have been part of this, in fact, the caregivers”.

MoreStories

Canada

See 9 high-demand Canadian jobs paying $50,000 or more in 2026 

January 28, 2026
US work permits, extension period for work permits, USCIS,

UK drops foreign student target, eyes £40bn education exports by 2030 

January 22, 2026

He also stated that the company will be donating 1.5 million vials of the intravenous drug. 

In the meantime, the company’s stock initially reacted negatively to this development, having declined by 4.8% to $79.95 as at close of market trading on the New York Stock Exchange, Friday. 

However, the stock reportedly went up by almost 2% during extended trading hours. Gilead Sciences’ valuation is a whopping $101 billion. 

What you should know: The emergency use authorisation for remdesivir does not mean that the drug has been given express approval by America’s Food and Drug Administration, FDA. As a matter of fact, the drug has not undergone any thorough review that would then give it the appropriate approval to treat patients. However, doctors can use it to treat patients for now due to the emergency nature of the Coronavirus pandemic. 

Researchers have, however, pointed out that remdesivir’s side effects could be as mild as nausea and vomiting, or as severe as liver damage. 

Recall that this is not the first time President Trump has been too eager to present a drug as a cure for the deadly virus. Recall that in March, Trump announced that the FDA approved the malaria drug – Chloroquine – as a cure for COVID-19. The FDA later faulted this claim.  


Add Nairametrics on Google News
Follow us for Breaking News and Market Intelligence.
Tags: FDAGilead Sciencesremdesivir drug
Emmanuel Abara Benson

Emmanuel Abara Benson

Emmanuel Abara Benson is an experienced business reporter and editor. He currently edits articles at Nairametrics. Reach him via email on Emmanuel.abara@nairametrics.com and follow him on Twitter @Mr_Abara for his personal opinions.

Next Post
Access Bank expands global footprint to France

“There will be no downsizing”, Access Bank assures its employees in spite of the pandemic

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

rabafast
NLNG

access bank
nairametrics








DUNS

Follow us on social media:

  • HOME
  • ABOUT NAIRAMETRICS
  • CONTACT US
  • DISCLAIMER
  • ADs DISCLAIMER
  • COPYRIGHT INFRINGEMENT

© 2026 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2026 Nairametrics